Rapid t-cell assay for sars-cov-2
AssigneeImmunityBio, Inc.
InventorsPeter Allan Sieling, Kayvan Niazi, Helty Adisetiyo, Philip T. Liu
Life of this patent
Estimating the term…
Abstract
Methods for detecting the presence of sever acute respiratory coronavirus 2 (SARS-CoV-2) are provided. The methods comprise incubating a sample comprising T-cells from an individual with one or more SARS-CoV-2 antigens, each antigen having a T-cell epitope, and detecting a change in state of T-cells in the sample. The change in state may be detected by determining the presence or level of a secreted, immune response indicator, such as interferon-gamma (IFN-γ).
Claims15
A method of detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an individual, the method comprising:
- a. incubating a sample in a container under conditions sufficient for specific recognition by T-cells, wherein the sample comprises T-cells from the individual, wherein the container comprises one or more SARS-CoV-2 antigens, wherein the one or more SARS-CoV-2 antigens are deposited on the interior surface of the container, and wherein the SARS-CoV-2 antigens comprise T-cell epitopes;
- and
- b. detecting a change of state in T-cells in a portion removed from the sample.
A composition comprising:
- a. one or more SARS-CoV-2 peptides, wherein the peptides consist of M, E, S, and/or N peptides;
- b. a container for the one or more SARS-COV-2 peptides;
- c. T-cells;
- and
- d. an antibody that binds to a T-cell immune response indicator;
- wherein each peptide comprises between 8 and 50 amino acids;
- and
- wherein the peptides comprise T-cell epitopes.
Dependencies are inferred from the claim text.